N/A N=10 The Effect of Electrical Stimulation on Impairment of the Painful Post-Stroke Shoulder
Stroke
Primary: Passive Range of Motion of Shoulder in Shoulder External Rotation — 66.9; 67.4; 69.1 degrees
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=274 Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure (COMPASS-HF)
Heart Failure
Primary: Safety as Measured by the Percentage of Participants Free From System Related Complications Through 6 Months. — 277 Participants
N/A N=23 Pilot Study of PDL to Treat BCC and SCCIS
Basal Cell Carcinoma · Squamous Cell Carcinoma in Situ
Primary: Tumor Clearance — 2; 2; 5 Participants
Phase 1 N=57 A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis
Adult Onset Rheumatoid Arthritis
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 13; 3; 7; 6 Participants
Phase 4 N=159 A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes
Type 2 Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — 0.06; -1.45 percentage of HbA1c — p=<0.001
N/A N=89 FIRE AND ICE Re-Ablations (Retrospective Data Collection)
Atrial Fibrillation · Paroxysmal Atrial Fibrillation
Primary: Number of Participants With Documented Atrial Arrhythmias Prior to Re-ablation — 36; 25; 7; 5 Participants
Phase 3 N=326 12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)
Bipolar Disorder
Primary: Least Squares Mean Change From Baseline in Young-Mania Rating Scale (Y-MRS) Score at Day 21 — 28.2; 27.9; -7.9; -10.3 Score on a Scale — p=0.0257
N/A N=449 Effect of Patient Information Leaflet on Working Pattern and Patient Satisfaction Level for Day Care Surgeries.
Patient Compliance
Primary: Number of Cases Postponed Due to Lack of Information to Patients in the Pre-operative Period — 56; 44 Participants
Phase 3 N=621 randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
Chronic Heart Failure With Reduced Ejection Fraction
Primary: Change From Baseline (Week 0) in the Six Minute Walk Test (6MWT) at End of Study (Week 12) — 365.37; 371.08; 395.80; 395.33 meters — p=0.2464
Phase 2 N=46 A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Primary: Percentage of Participants Who Achieved a Complete Response (CR) at the End of Induction Therapy — 54.1; 66.7 percentage of participants
N/A N=45 Nintendo WII and Exercises at Rehabilitation of Individuals With Parkinson's Disease
Parkinson Disease
Primary: Berg Balance Scale — 40.5; 43.9; 41.6; 45.6 Score on a scale
N/A N=23 Fitbit and Social Support in Knee Replacement Patients & Buddies
Arthroplasty, Replacement, Knee
Primary: Moderate/Vigorous Intensity Physical Activity — 26.9; 33.1 minutes/day
Phase 3 N=18 Extension Study for Patients Entered Into Study Infacort 003
Adrenal Insufficiency
Primary: Incidence of Serious Adverse Events (SAEs) and Adverse Events (AEs) — 193; 9; 0; 42 adverse events
Phase 2 N=108 Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Central Nervous System Neoplasm · Pineoblastoma · Recurrent Medulloblastoma
Primary: Overall Survival — 2.43; 13.6 percent probability
N/A N=849 The Electronic Asthma Action Plan System for Implementation in Primary Care
Asthma
Primary: Number of Participants to Whom an AAP (Asthma Action Plan) Was Delivered by the Clinician — 0; 79 Participants